College of Medicine College of Medicine

News/Events/Seminars
50th Anniversary Celebration
Faculty
History
Pharmacology Graduate Program
Interdisciplinary Toxicology Graduate Program
Available Courses
Postdoctoral Training
SURF Program
Meet Our Students
Contact Us
Faculty Positions
UAMS College of Medicine
UAMS Graduate School
UAMS Home
Department Homepage

Update Alumni



S. Michael Owens, Ph.D.
Professor and Director, Center for Alcohol and Drug Abuse, and a Wilbur Mills Endowed Chair in Alcohol and Drug Abuse Prevention

S. Michael Owens, Ph.D.
PHD
University of North Carolina, Chapel Hill, 1980

Research Interests
The objective of my research program is to develop antibody-based medications for use in treating the neurological problems associated with drug abuse. The projects involve the integration of multidisciplinary basic science studies with the application of these scientific discoveries to the treatment of human disease. These studies utilize molecular design, hybridoma technology, antibody engineering techniques, as well as studies of the effects of drug of abuse on brain function. Large scale production of antibodies as drugs is accomplished through the use of bioreactors, along with the development of the technology for the molecular and biological engineering of plant-derived antibodies. For the in vivo testing of the antibody-based medications, a comprehensive series of pharmacokinetic/pharmacodynamic studies following active and passive immunization are being conducted in animal models of human drug abuse. A major goal of these studies is to better understand the mechanism by which these new medications can be used to treat adverse chemical effects on the central nervous system. Thus, these studies are serving as a prototypic system to acquire knowledge that can be applied to antibody-based therapy for a wide variety of human diseases.

E-mail
owenssamuelm@uams.edu


Selected Publications

Hendrickson, HP, Whaley, CE and Owens, SM: A validated liquid chromatography tandem mass spectrometric method for the determination of phencyclidine in microliter Samples of Rat Serum. J Mass Spectrom 10: 19-24, 2005.

Kosten, T. and Owens, S.M. Immunotherapy for the treatment of drug abuse. In Discovery, Development and Implementation of Novel Pharmacotherapies for Addiction. Pharmacol Ther. T.C. Napier and F.J. Vocci, Ed. 18: 76-85 2005.

Milesi-Hallé, A., Hendrickson, H.P., Laurenzana, E.M., Gentry, W.B., and Owens, S.M.: Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in Rats. Toxicol Appl Pharmacol 209:302-213, 2005.

Byrnes-Blake K.A., Laurenzana E.M., Landes R.D., Gentry W.B. and Owens S.M.: Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine Effects in Rats. Eur J Pharmacol 251:86-94. 2005.

Daniels, J.R., Wessinger, W.D., Hardwick, W.C., Li, M., Gunnell, M.G., Hall, C.J., Owens, S.M.: and McMillan, DE: Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibody alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine. Psychopharmacol 185:36-44 2006.

Gentry W.B., Laurenzana E.M., Williams D.K., West J.R., Berg R.J., Terlea T., and Owens S.M. Safety and Efficiency of an anti-(+)-methamphetamine monoclonal IgG in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int Immunopharmacol, 6:968-977 2006.

Pitas G., Laurenzana E.M., Williams D.K., Owens S.M., and Gentry W.B. Anti-PCP monoclonal antibody binding capacity is not the only determinant of effectiveness, disproving the concept that antibody capacity is easily surmounted. Drug Metab Dispos, 34:906-912 2006

Peterson, E., Owens, S.M. and Henry, R.L.: Monoclonal antibody form and function: Manufacturing the right antibodies for treating drug abuse. AAPS J 8(2): E383-390 2006.

Hendrickson, H.P., Laurenzana, E.M. and S.M. Owens: Quantitative Determination of Total Methamphetamine and Active Metabolites in Rat Tissue by Liquid Chromatography With Tandem Mass Spectrometric Detection. AAPS , E709-E717, 2006.

Milesi-Hallé, A., McMillan, D.E., Laurenzana, E.M., Byrnes-Blake, K. and Owens, S.M. Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavior in male and female Sprague-Dawley rats. Pharmacol Biochem Behav,. 86:140-149, 2007.

Peterson, E.C., Gunnell, M.G., Che, Y., Goforth, R.L. Carroll, F.I., Henry, R., and S.M. Owens: Using Hapten Design to Discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther, In press.


University of Arkansas for Medical Sciences
Department of Pharmacology and Toxicology

4301 West Markham Street, Slot 611
Little Rock, AR 72205
(501) 686-5510
Contact: Webmaster.